Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor

Authors:

Abstract
Psoriatic patients have a higher prevalence of diabetes mellitus type 2 (DM). Since dipeptidyl peptidase IV (DPP‐IV) dysregulation is present in DM and psoriasis, DPP‐IV inhibitors have been proposed as therapeutic agents for both conditions. We report a psoriasiform eruption induced by sitagliptin, a DPP‐IV inhibitor. The role of DPP‐IV in the pathogenesis of DM is well established; however data on psoriatic patients is contradictory. More studies are required to elucidate the effect of DPP‐IV inhibitors and their relationship with DM and psoriasis.

This publication has 13 references indexed in Scilit: